Welcome to our dedicated page for XOMA Royalty news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty stock.
XOMA Royalty Corporation operates as a biotechnology royalty aggregator that acquires rights to potential milestone and royalty payments tied to therapeutic candidates licensed to pharmaceutical and biotechnology companies. Its updates commonly address portfolio additions, royalty-sharing transactions, commercial and development-stage assets, clinical and regulatory disclosures from underlying programs, and cash receipts from royalties and milestones.
Company news also covers financial results, preferred stock dividends on its Series A and Series B cumulative preferred securities, completed acquisitions that expand the royalty portfolio, and executive or governance changes. Named portfolio assets include VABYSMO, OJEMDA, MIPLYFFA, XACIATO, IXINITY, DARE to PLAY, DSUVIA, and development-stage assets such as mezagitamab.
XOMA Corporation reported Q3 2021 financial results, noting total revenues of $0.9 million, a rise from $0.6 million in Q3 2020. A $0.5 million milestone was earned from Compugen after AstraZeneca dosed the first patient in a study of AZD2936. R&D expenses were $30,000, while G&A expenses increased to $4.3 million. The net loss expanded to $4.4 million from $1.1 million a year earlier. XOMA held $68.8 million in cash at quarter-end, down from $84.2 million at the end of 2020, yet confident it can fund operations for multiple years.
XOMA Corporation (NASDAQ: XOMA) announced that CEO Jim Neal will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 28, 2021, at 10:20 AM PT. As a biotechnology royalty aggregator, XOMA plays a crucial role in advancing health by acquiring future economics from pre-commercial therapies, providing non-dilutive funding for biotech companies. The company manages over 70 assets linked to therapeutic candidates, enhancing its portfolio and potential revenue streams. Visit www.xoma.com for more details.
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its preferred stockholders. The holders of the 8.625% Series A Cumulative Perpetual Preferred Stock will receive a dividend of $0.53906 per share. Holders of the 8.375% Series B Cumulative Perpetual Preferred Stock will receive $0.52344 per depositary share. These dividends will be paid on or about October 15, 2021, to shareholders on record as of October 1, 2021.
XOMA Corporation announced that CEO Jim Neal will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference from September 13-15, 2021. The presentation will be available on demand starting September 13, 2021, at 7:00 AM ET. Interested parties can access it through the link or via XOMA's investor relations section. A replay will be available for 90 days.
XOMA Corporation (NASDAQ: XOMA) has appointed Heather L. Franklin, President and CEO of Blaze Bioscience, to its Board of Directors. With over 20 years in biotechnology, Franklin brings extensive experience in corporate development and strategy. She is recognized for negotiating significant deals, including a notable $1.1 billion collaboration with Bristol Myers Squibb. XOMA aims to enhance its royalty aggregator model by leveraging Franklin’s expertise in licensing and transactions to grow its portfolio of royalty assets.
XOMA Corporation announced its Q2 2021 financial results, reporting total revenues of $0.9 million, up from $0.4 million in Q2 2020, driven by a $0.5 million milestone from Janssen. Operating cash at quarter-end was $78.9 million, with no outstanding debt. The company raised $40 million through a preferred stock offering. Noteworthy developments include Orphan Drug Designation for NIS793 in pancreatic cancer and Rare Pediatric Disease Designation for DAY101. Despite a net loss of $2.2 million, XOMA's strong balance sheet supports future growth.
XOMA Corporation (NASDAQ: XOMA) has announced that NIS793, an investigational antibody targeting Transforming Growth Factor Beta (TGFβ), has received Orphan Drug Designation from the FDA for pancreatic cancer treatment. This designation provides various benefits to encourage drug development for rare diseases. Upon regulatory approval of NIS793, XOMA could earn up to $445 million through milestone payments and receive tiered royalties on net product sales. However, efficacy and safety of NIS793 have not yet been established, and commercialization is not guaranteed.
XOMA Corporation has acquired a royalty interest in Checkmate Pharmaceuticals’ therapy vidutolimod for $7 million, with potential sales milestones. Vidutolimod, a Toll-like receptor 9 agonist, aims to enhance the immune response against tumors, particularly in melanoma patients. The FDA has granted Fast Track and Orphan Drug designations for this treatment. XOMA stands to gain additional pre-commercial milestone payments of up to $25 million, positioned to benefit from future sales as Checkmate conducts multiple clinical studies to advance vidutolimod.
XOMA Corporation announced cash dividends for its preferred stockholders. Holders of 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive $0.539 per share, while holders of 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will receive $0.55833 per depositary share. The dividends are scheduled for payment on July 15, 2021, to shareholders of record as of July 2, 2021. XOMA also operates as a biotechnology royalty aggregator, acquiring potential future economics associated with drug candidates that have been licensed to other pharmaceutical firms.
XOMA Corporation (Nasdaq: XOMA) announced its licensees will present at the 2021 ASCO Annual Meeting from June 4-8. CEO Jim Neal expressed excitement over Novartis and AVEO's advancements with drug candidates NIS793 and ficlatuzumab, respectively, which are moving towards Phase 3 clinical programs. The presentations will showcase their investigational compounds, with efficacy and safety still unproven. Investors should note that there is no guarantee these drugs will reach commercial availability.